The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

Six years into espnW Summit NYC, brands increasingly want in on the gathering of institutional women's sports knowledge. In ...

Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...

Shares in pharmaceuticals giant Eli Lilly (LLY) were looking perkier today after it ramped up its battle to get a key ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Eli Lilly and Company LLY will report its first-quarter earnings on May 1, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.62 billion and $3.52 per share, ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential.

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...